Importantly, reduced FREM1 expression correlates with aggressive clinicopathological features including advanced TNM stage and poorer survival outcomes, while also associating with an immunosuppressive tumor microenvironment marked by diminished cytotoxic lymphocyte infiltration and increased immunosuppressive cell populations [46, 47]. Here, FREM1 is linked to neoplasm.